{"public_id":"cl_cd6b0fe3173b040391554e40b81bfefb","status":"active","superseded_by_public_id":null,"corpus_id":11443010,"text":"Osmotic-release oral system methylphenidate also showed statistically significant improvements relative to placebo throughout the day, but the trial was not designed to support a statistical comparison with lisdexamfetamine dimesylate.","confidence":0.93,"paper":{"corpus_id":11443010,"title":"Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial","url":"https://sah.borca.ai/papers/11443010"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.93,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_85a11651753473842ba2a764dd4eb516","name":"osmotic-release oral system methylphenidate","description":"A long-acting methylphenidate formulation used as a reference treatment in the trial.","types":["drug","reference treatment"],"url":"https://sah.borca.ai/concepts/co_85a11651753473842ba2a764dd4eb516"},{"public_id":"co_dada3d031efb764640f1e89bcf84e0ed","name":"lisdexamfetamine dimesylate","description":"A long-acting prodrug stimulant therapy used for treating attention-deficit/hyperactivity disorder.","types":["drug","stimulant therapy"],"url":"https://sah.borca.ai/concepts/co_dada3d031efb764640f1e89bcf84e0ed"},{"public_id":"co_dffc7a2d7f55f760526cb7a7678acad0","name":"placebo","description":"An inactive control treatment used for comparison in the trial.","types":["control"],"url":"https://sah.borca.ai/concepts/co_dffc7a2d7f55f760526cb7a7678acad0"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_cd6b0fe3173b040391554e40b81bfefb"}